# The National Security and Investment Act 2021 (Notifiable Acquisition) (Specification of Qualifying Entities) Regulations 2021, Paragraph 5: Exceptions - general


Exceptions to the activities described in paragraph 2 are—
(a) general services or servicing not related to core synthetic biology, where “core” means those activities without which experiments cannot be conducted, such as DNA synthesis or cloning;
(b) the use of microorganisms to remove harmful contaminants, pollutants or toxins from the environment (known as bioremediation), including bio-based reagents that allow for testing for contaminants;
(c) any approach used to gather clinical information for the purpose of making a clinical decision or making a diagnosis (known as diagnostics) but not the storage or ownership of sensitive human genetic information that enables the identification of an individual;
(d) industrial biotechnology research, development or production using enzymes or organisms that have not been modified through the application of synthetic biology;
(e) the production of substances ordinarily consumed as food or used as feed, including any ingredient or component of such substances;
(f) gene therapy, where it is used solely for the purpose of replacing missing or defective genes to restore phenotypes to achieve a therapeutic effect;
(g) cell therapy, where cells are modified by genetic engineering and then introduced into a patient to treat disease.

---
Source: https://www.legislation.gov.uk/ukdsi/2021/9780348226935/schedule/16/paragraph/5 (the official version)
Page: https://openlegislation.uk/draft-national-security-and-investment-act-2021-notifiable-acquisition-specification-of-qualifying-entities-regulations-2021/schedule-16/paragraph-5
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.

